Gamma-aminobutyric acid type A receptor subunit alpha5 (GABAA α5 receptor)

The gamma-aminobutyric acid type A receptor subunit alpha5 (GABAA α5 receptor) is a subunit of the pentameric ligand-gated chloride ion channel that mediates inhibition in the central nervous system in response to the neurotransmitter GABA. GABAA α5-containing receptors are typically found in both synaptic and extrasynaptic locations, exhibiting high expression in the hippocampus where they underlie a specific form of tonic inhibition critical for cognitive processing. These receptors are of particular therapeutic interest due to their unique role in regulating cognition, learning, and memory, making them a target for drugs intended to enhance cognitive function or treat neurodevelopmental and neuropsychiatric disorders. Selective modulation of the α5 subunit has shown promise for cognitive enhancement with reduced side effects compared to non-selective GABAA modulators. Both positive and negative allosteric modulators, as well as competitive antagonists, have been developed to selectively target this subtype, and current research focuses on exploiting its unique distribution and function to develop precision therapies for CNS disorders[3][4][6][8].

Other names

GABAA α5GABA(A) receptor alpha5 subunitGABRA5

Negative allosteric modulation (NAM) at the benzodiazepine site; Positive allosteric modulation (PAM) at the benzodiazepine site; Competitive antagonism at the GABA binding site